EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm

Andrew A Lane iD, Marlise R Luskin iD, Julia Keating, Nicole R LeBoeuf iD, Jacqueline S Garcia iD, Shai Shimony iD, Rebecca Leonard, Adon Goodpaster, Theresa T Nguyen, Ilene Galinsky, Ashleigh Eberly-Puleo, Naval Daver iD und 6 weitere

Blood · 29.10.2026 · 148 (18) · 2229-2238

DOI: 10.1182/blood.2026033906 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 29.10.2026. Verfasst von Andrew A Lane und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Blastic Plasmacytoid Dendritic Cell Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan, aggressive hematologic malignancy characterized by high CD123 expression. Tagraxofusp (TAG), a CD123-directed toxin, is the first approved therapy. Prior studies demonstrated BPDCN dependence on BCL2, sensitivity to venetoclax (VEN), and reversal of TAG resistance with azacitidine (AZA). We conducted a phase 2 study evaluating combination therapy with TAG, AZA, and VEN in patients with BPDCN. Patients with previously untreated (1L) or relapsed/refractory (R/R) BPDCN received 28-day cycles of AZA (75 mg/m2 on days 1-7), VEN (400 mg on days 1-21), and TAG (12 μg/kg on days 4-6). Eligibility followed TAG guidelines to mitigate risk of capillary leak syndrome (CLS). Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range, 21-81). Composite complete remission (composed of: complete remission [CR], CR with incomplete count recovery, and CR clinical) rates were 88% in 1L and 64% in R/R cohorts. Median duration of response was not reached in 1L and was 7.2 months in R/R patients. CLS occurred in 15% of patients, most were grade 2. In the 1L cohort, median overall survival (OS) and progression-free survival (PFS) were not reached; the 2-year OS was 65% and 2-year PFS was 53%. Median OS in R/R patients was 8.4 months. A high proportion of patients proceeded to allogeneic stem cell transplantation in remission (63% in 1L, including 10/11 patients aged ≤75 years; 55% in R/R). TAG-AZA-VEN is highly active in both 1L and relapsed BPDCN with a predictable and manageable safety profile, supporting its use as a new therapeutic option. This trial was registered at www.clinicaltrials.gov as #NCT03113643.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blastic Plasmacytoid Dendritic Cell NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleSulfonamidesAgedBridged Bicyclo Compounds, HeterocyclicMaleAzacitidineMiddle AgedAged, 80 and overAdultExotoxinsRecombinant Fusion Proteins

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicAzacitidinetagraxofuspExotoxinsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.

ORCID-Profile: Andrew A Lane, Marlise R Luskin, Nicole R LeBoeuf, Jacqueline S Garcia, Shai Shimony, Naval Daver, Marina Y Konopleva, Naveen Pemmaraju

Zitieren

APA

Lane, A. A., Luskin, M. R., Keating, J., LeBoeuf, N. R., Garcia, J. S., Shimony, S., Leonard, R., Goodpaster, A., Nguyen, T. T., Galinsky, I., Eberly-Puleo, A., Daver, N., Jain, N., Garcia-Manero, G., Kantarjian, H., Konopleva, M. Y., Stein, A., & Pemmaraju, N. (2026). Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood, 148(18), 2229-2238. https://doi.org/10.1182/blood.2026033906

Vancouver

Lane AA, Luskin MR, Keating J, LeBoeuf NR, Garcia JS, Shimony S, et al. Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood. 2026;148(18):2229-2238. doi:10.1182/blood.2026033906

BibTeX
@article{Lane2026,
  author = {Lane, Andrew A and Luskin, Marlise R and Keating, Julia and LeBoeuf, Nicole R and Garcia, Jacqueline S and Shimony, Shai and Leonard, Rebecca and Goodpaster, Adon and Nguyen, Theresa T and Galinsky, Ilene and Eberly-Puleo, Ashleigh and Daver, Naval and Jain, Nitin and Garcia-Manero, Guillermo and Kantarjian, Hagop and Konopleva, Marina Y and Stein, Anthony and Pemmaraju, Naveen},
  title = {Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {18},
  pages = {2229--2238},
  doi = {10.1182/blood.2026033906}
}
Kostenlos starten →